Search for: "Generic Pharmaceutical Services, Inc."
Results 461 - 480
of 1,029
Sort by Relevance
|
Sort by Date
6 Aug 2013, 6:03 pm
” Unfortunately, HHS kicked off this campaign on the same day that the HHS’s Office of Inspector General (OIG) released a report titled Observations Noted During The OIG Review Of CMS’s Implementation Of The Health Insurance Exchange—Data Services Hub (Report) that raises questions about the adequacy of the current security of the data portal and whether HHS will complete the arrangements and testing to verify it appropriately safeguards the security of… [read post]
29 Jul 2013, 7:45 am
In In re Rigel Pharmaceuticals, Inc. [read post]
23 Jul 2013, 6:30 am
©2013 Amaxx Risk Solutions, Inc. [read post]
16 Jul 2013, 6:30 am
©2013 Amaxx Risk Solutions, Inc. [read post]
8 Jul 2013, 6:30 am
©2013 Amaxx Risk Solutions, Inc. [read post]
5 Jul 2013, 5:00 am
Astra Pharmaceutical Products, Inc., 993 F.2d 528, 538 (6th Cir. 1993). [read post]
28 Jun 2013, 6:01 pm
Praxair Canada Inc., [1998] O.J. [read post]
27 Jun 2013, 12:30 pm
The Department of Health and Human Services (HHS) Office of Inspector General (OIG) recently announced that it expects to recover an estimated $3.8 billion in overall recoveries for the first half of fiscal year 2013. [read post]
27 Jun 2013, 6:30 am
©2013 Amaxx Risk Solutions, Inc. [read post]
25 Jun 2013, 9:51 am
Watson Pharmaceuticals, Inc. [5] Citing FTC v. [read post]
25 Jun 2013, 6:52 am
In the pharmaceutical field, they could also delay the marketing of generic drugs, to the detriment of both competitors and consumers. [read post]
24 Jun 2013, 12:50 pm
Ortho Pharmaceutical Corp., 642 F.2d 652 (1st Cir. 1981), made of New Hampshire law. [read post]
24 Jun 2013, 10:08 am
Watson Pharmaceuticals, Inc. [5] Citing FTC v. [read post]
24 Jun 2013, 6:08 am
Watson Pharmaceuticals, Inc. [5] Citing FTC v. [read post]
21 Jun 2013, 6:43 pm
Philip Morris USA, Inc., 449 F. [read post]
21 Jun 2013, 4:46 am
Liggett Group – that federal law does not preempt state law design-defect claims targeting generic pharmaceutical products because the conceded conflict between such claims and the federal laws governing generic pharmaceutical design allegedly can be avoided if the makers of generic pharmaceuticals simply stop making their products. [read post]
16 Jun 2013, 3:49 pm
Liggett Group – that federal law does not preempt state law design-defect claims targeting generic pharmaceutical products because the conceded conflict between such claims and the federal laws governing generic pharmaceutical design allegedly can be avoided if the makers of generic pharmaceuticals simply stop making their products. [read post]
12 Jun 2013, 10:16 am
The agent is RX Processing Services Inc. [read post]
10 Jun 2013, 11:38 am
Liggett Group – that federal law does not preempt state law design-defect claims targeting generic pharmaceutical products because the conceded conflict between such claims and the federal laws governing generic pharmaceutical design allegedly can be avoided if the makers of generic pharmaceuticals simply stop making their products. [read post]
6 Jun 2013, 12:15 am
The doctrine of inherent anticipation (particularly after Schering Co. v Geneva Pharmaceuticals Inc. et Al., commented here - see also, in the UK, Merrell Dow v H N Norton & Co), may lead to similar distortions. [read post]
